QuantRx Biomedical Corporation (QTXB)

0.0040 0.0000 (0.00%) As of 02:37PM EDT. Market open.

QuantRx Biomedical Corporation

10190 SW 90th Avenue
Tualatin, OR 97062
United States
212 980 2235
https://www.quantrx.com/index.htm

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Shalom Z. Hirschman M.D.	Chairman of the Board, CEO & Principal Accounting Officer	N/A	N/A	1936

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.

Corporate governance

QuantRx Biomedical Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.